2023-03-13 16:50:51 ET
- Viracta Therapeutics press release ( NASDAQ: VIRX ): Q4 GAAP EPS of -$0.27 beats by $0.12 .
- Cash, cash equivalents and short-term investments totaled approximately $91.0 million as of December 31, 2022, which Viracta expects will be sufficient to fund its operations into late 2024, excluding any additional borrowing under a $50.0 million credit facility, of which $25.0 million remains available, at the Company’s request, subject to the discretion of the lenders.
For further details see:
Viracta Therapeutics GAAP EPS of -$0.27 beats by $0.12